Pacira Pharmaceuticals buy Barclays PLC
Start price
08.05.24
/
50%
€26.80
Target price
08.05.25
€35.35
Performance (%)
-47.39%
Price
02.09.24
€13.80
Summary
This prediction is currently active. The BUY prediction by Barclays_PLC for Pacira Pharmaceuticals is performing very badly with a performance of -47.39%. This prediction currently runs until 08.05.25. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 7.813% | 7.813% |
iShares Core DAX® | 1.663% | 6.945% |
iShares Nasdaq 100 | 1.261% | 4.883% |
iShares Nikkei 225® | 0.654% | 10.007% |
iShares S&P 500 | 1.403% | 4.350% |
Comments by Barclays_PLC for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $40.00 to $38.00. They now have an "overweight" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Barclays_PLC for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.20
23.10.23
23.10.23
€53.51
23.10.24
23.10.24
-46.56%
02.09.24
02.09.24